Pilot Clinical Trial to Evaluate the UNI-DEB for Unresectable Hepatocellular Carcinoma

Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous Therapy

NCT06496815 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4

Phase 2 Study of ADI-PEG 20 Plus Lenvatinib Treatment in Subjects With Unresectable Hepatocellular Carcinoma

NCT06034977 ·Status: RECRUITING ·Phase: PHASE2

Clinical Feasibility of Microwave Ablation Using Two Channel Microwave Generator and Two Antennas for Small Hepatocellular Carcinoma

NCT06086002 ·Status: COMPLETED ·Phase: NA

The Safety and Efficacy of Deferoxamine for Treating Unresectable Hepatocellular Carcinoma

NCT03652467 ·Status: UNKNOWN ·Phase: PHASE1

The Effect of Viral Load on Intrahepatic Recurrence in Hepatitis B Virus (HBV)-Related Hepatocellular Carcinoma (HCC)

NCT00397540 ·Status: COMPLETED ·Phase: NA

Study of ADI-PEG 20 Versus Placebo in Subjects With High Arginine Level and Unresectable Hepatocellular Carcinoma

NCT05317819 ·Status: RECRUITING ·Phase: PHASE3

Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By Surgery

NCT00321594 ·Status: COMPLETED ·Phase: PHASE1/PHASE2

Gefitinib in Treating Patients With Advanced Unresectable Hepatocellular Carcinoma (Liver Cancer)

NCT00071994 ·Status: COMPLETED ·Phase: PHASE2

A Study To Evaluate The Efficacy And Safety of The Investigational Drug PF-03446962 (A Monoclonal Antibody With Antiangiogenic Features) In Combination With Best Supportive Care Versus Placebo Plus Best Supportive Care In Patients Affected By Recurrent Liver Cancer

NCT01911273 ·Status: TERMINATED ·Phase: PHASE2

Anti-angiogenic Agents Plus Anti-PD-1 Antibodies for uHCC

NCT04639284 ·Status: UNKNOWN

A Prospective, Multicenter, Phase II Clinical Study on the Treatment of Unresectable Advanced HCC with DEB-TACE Combined with SALOX-HAIC

NCT06823050 ·Status: NOT_YET_RECRUITING

Jiu-wei-zhen-xiao Granule for Advanced Hepatocellular Carcinoma

NCT03851471 ·Status: COMPLETED ·Phase: EARLY_PHASE1

Cadonilimab and Lenvatinib for Conversion Therapy in Unresectable Hepatocellular Carcinoma

NCT06215651 ·Status: RECRUITING ·Phase: PHASE2

A Trial of Behavioral Intervention on Prognostic Survival of Patients With Unresectable Liver Cancer

NCT07337031 ·Status: NOT_YET_RECRUITING ·Phase: NA

A Prospective Cohort Study of Patients with Hepatobiliary Cancer Treated with Immune Checkpoint Inhibitors

NCT03695952 ·Status: ACTIVE_NOT_RECRUITING

PVE/PVL Combined With DEB-TACE in the Treatment of Patients With Large and Unresectable Liver Cancer

NCT05103007 ·Status: RECRUITING ·Phase: NA

Gecacitinib Combined With Donafenib and PD-1 Inhibitor as Immune Rechallenge Therapy for Unresectable Hepatocellular Carcinoma

NCT07157306 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

"cindilizumab + Bevacizumab + Coenzyme I for Injection" in Unresectable Hepatocellular Carcinoma

NCT06590844 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE4

Phase II Study of Avelumab in Patients With Advanced Hepatocellular Carcinoma After Prior Sorafenib Treatment

NCT03389126 ·Status: COMPLETED ·Phase: PHASE2

Proton Beam Therapy for Unresectable Liver Metastasis

NCT04456621 ·Status: COMPLETED ·Phase: NA

Neoadjuvant Anti-PD1 in HCC

NCT05471674 ·Status: COMPLETED ·Phase: PHASE2

The Treatment of Unresectable Liver Cancer With E-TACE Combined With Donafenib：A Prospective, Single-arm, Multicenter, Observational Study

NCT07180459 ·Status: NOT_YET_RECRUITING

Anti-PD-1/PD-L1 Combined With Anti-angiogenic Agents as First-line Treatment for Unresectable HCC

NCT06360042 ·Status: RECRUITING ·Phase: PHASE2

Erlotinib in Treating Patients With Unresectable Liver, Bile Duct, or Gallbladder Cancer

NCT00033462 ·Status: COMPLETED ·Phase: PHASE2

Precision Treatment of Unresectable HCC Guided by Multi-omics Deep Learning Models

NCT06463444 ·Status: RECRUITING ·Phase: PHASE1